Orthocell has identified a promising new application for its flagship Remplir\u2122 nerve repair device – for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP).<\/p>\n
Currently up to 80% of men experience erectile dysfunction, and up to 35% suffer from urinary incontinence, after radical prostatectomy due to damage of the peripheral nerves in the neurovascular bundle (NVB) surrounding the prostate.<\/p>\n
Australian urologists are using Remplir to protect the NVB from damage and promote restoration of normal nerve function, with approximately 40 surgical cases completed to date. Orthocell is collaborating with surgeons to collate this clinical data for analysis, which will be released once available.<\/p>\n
Orthocell CEO and MD, Paul Anderson, said:<\/p>\n
\u201cThe use of Remplir\u2122 in nerve-sparing robotic-assisted radical prostatectomy highlights the product\u2019s versatility and superior performance in the protection and reconstruction of damaged peripheral nerves.<\/p>\n
Surgeons across multiple specialties\u2014including orthopaedics, plastic and reconstructive surgery, and now urology\u2014are increasingly adopting Remplir to simplify procedures, minimise scarring, and improve functional recovery.<\/p>\n
This represents a significant step forward in Remplir\u2019s organic expansion into broader peripheral nerve repair applications and has the potential to substantially increase the device\u2019s global total addressable market.\u201d<\/p>\n